To print: Select File and then Print from your browser's menu

Title: Insulin-Like Growth Factor-1 Does Not Promote Linear Growth In Children With Cystic Fibrosis

URL: http://ipsapp006.lwwonline.com/servlet/GetFileServlet?J=2960&I=11&A=12&U=1&T=0

J Pediatr Gastroenterol Nutr 2001; 33(5): 576-581. "Effect of Insulinlike Growth Factor-1 Treatment in Children With Cystic Fibrosis"
12/20/2001 09:52:43 AM
By James Adams

Six months of treatment with insulin-like growth factor-1 (IGF-1) failed to promote linear growth in prepubertal children with cystic fibrosis. Although IGF-1 failed to promote this growth, it significantly increased the glucose/insulin ratio, which is an indirect measure of insulin sensitivity. "Malnutrition is common in cystic fibrosis (CF) and adversely affects survival," according to investigators from the University of Cincinnati School of Medicine in Cincinnati, Ohio, United States. The investigators hypothesized that IGF-1 would increase linear growth and decrease insulin requirements in children with CF as a result of its known insulin-like effects on carbohydrate metabolism and its growth promoting characteristics. A double-blind, placebo-controlled, crossover study including seven prepubertal children between 9.6 and 13 years of age was conducted. The five boys and two girls received placebo or IGF-1 for six months, followed by a six-month washout period, then they received the alternative treatment for an additional six months. With IGF-1 treatment, mean serum IGF-1 levels increased two- to three-fold in all the patients, and half-life for IGF-1 was 10.3 hours. There was no significant difference in linear growth rate, weight gain, rate of accretion of lean body mass or mean forced expiratory volume with IGF-1 treatment compared with placebo. A significant increase in the glucose/insulin ratio occurred with IGF-1 treatment, suggesting an increase in insulin sensitivity.

http://ipsapp006.lwwonline.com/servlet/GetFileServlet?J=2960&I=11&A=12&U=1&T=0

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.